Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

24.85 -1.19 (-4.57%)

Delayed Quote Updated: 1:49 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Amphastar Receives FDA Approval for Vasopressin

July 19, 2022

Via ACCESSWIRE

Amphastar Receives FDA Approval for Vasopressin

July 19, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating ↗

July 15, 2022

Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level.

Via Investor's Business Daily

Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5 ↗

July 15, 2022

The group has several commonalities, including strong ratings and promising charts.

Via Investor's Business Daily

Prometheus Biosciences Stock Shows Rising Relative Strength ↗

July 14, 2022

Prometheus Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 72 to 90.

Via Investor's Business Daily

Merus Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

July 14, 2022

On Thursday, Netherlands-based Merus stock had its Relative Strength (RS) Rating upgraded to 94 from 78 a day earlier.

Via Investor's Business Daily

Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗

July 13, 2022

ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level.

Via Investor's Business Daily

Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗

July 11, 2022

On Monday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 91 Monday, up from 85 a day earlier.

Via Investor's Business Daily

Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8% ↗

July 11, 2022

Among its other key ratings, Amsterdam-based gene therapy company Uniqure stock also has a 92 Composite Rating.

Via Investor's Business Daily

Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91 ↗

July 05, 2022

Global Blood Therapeutic stock saw a positive improvement to its Relative Strength Rating on Tuesday, rising from 85 to 91.

Via Investor's Business Daily

Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96 ↗

June 30, 2022

Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 96 Thursday, up from 94 the day before.

Via Investor's Business Daily

Kura Oncology Stock Scores Rising Relative Strength ↗

June 30, 2022

On Thursday, Kura Oncology stock had its Relative Strength (RS) Rating stock upgraded to 93 from 81 a day earlier.

Via Investor's Business Daily

Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92 ↗

June 30, 2022

Syndax Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 80 to 92.

Via Investor's Business Daily

Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating ↗

June 28, 2022

Amylyx Pharmaceuticals stock reached an key technical benchmark, with its Relative Strength Rating climbing to 95, up from 70 the day before.

Via Investor's Business Daily

Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

June 15, 2022

Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 09, 2022

Via Benzinga

69 Biggest Movers From Yesterday ↗

June 10, 2022

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday.

Via Benzinga

36 Stocks Moving In Thursday's Mid-Day Session ↗

June 09, 2022

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) jumped 65% to $0.6382.

Via Benzinga

Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference

June 06, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)

June 06, 2022

Via AB Newswire

Amphastar Pharmaceuticals's Return On Capital Employed Insights ↗

June 02, 2022

Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) posted Q1 earnings of $24.25 million, an increase from Q4 of 22.74%. Sales dropped to $120.37 million, a 0.43% decrease between...

Via Benzinga

United Therapeutics Stock Sees RS Rating Jump To 89; Earns 'Blue Dot' ↗

May 24, 2022

United Therapeutics stock had its Relative Strength (RS) Rating upgraded to 89 Tuesday, from 71 a day earlier.

Via Investor's Business Daily

Amphastar Receives FDA Approval for Regadenoson

May 24, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

7 Safe Small-Cap Stocks to Buy Now ↗

May 12, 2022

If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy.

Via InvestorPlace

Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

May 11, 2022

Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.

Via Investor's Business Daily

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022

May 09, 2022

Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022

May 02, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗

April 14, 2022

On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

April 12, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

10 Stocks That Have Moved Over 20% Since The Indices Plummeted ↗

April 08, 2022

The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.